UBS Group
TGTX icon

UBS Group’s TG Therapeutics TGTX Stock Holding History

UBS Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-144,400
Closed -$5.2M – 10922
2025
Q2 		$5.2M Buy
+144,400
New +$5.38M ﹤0.01% 3846
2015
Q1 		– Sell
-100
Closed -$2K – 9364
2014
Q4 		$2K Buy
+100
New +$1.3K ﹤0.01% 9426

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

UBS Group's TGTX Position: Q2 2026 in Review

UBS Group increased its TG Therapeutics (TGTX) stake by 1.9% in Q2 2026, buying an estimated $389K and bringing the position to 515,162 shares worth $28.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2320.

UBS Group first reported a position in TGTX in Q4 2014 and has held it in 47 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • UBS Group held 515,162 shares of TG Therapeutics worth $28.3M as of Q2 2026.
  • UBS Group bought 9,512 TG Therapeutics shares in Q2 2026, an estimated $389K.
  • TG Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2320 holding.
  • UBS Group first reported a position in TG Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.